Details of the Active Pharmaceutical Ingredient (API)
General Information of API (ID: D00093) | |||||
---|---|---|---|---|---|
Name |
Canagliflozin
|
||||
Synonyms |
Click to Show/Hide the Synonyms of This API
Canagliflozin; 842133-18-0; Canagliflozin anhydrous; canagliflozin hemihydrate; TA-7284; JNJ-28431754; UNII-6S49DGR869; JNJ 24831754ZAE; Canagliflozin hydrate; 1-(Glucopyranosyl)-4-methyl-3-(5-(4-fluorophenyl)-2-thienylmethyl)benzene; (2S,3R,4R,5S,6R)-2-(3-((5-(4-FLUOROPHENYL)THIOPHEN-2-YL)METHYL)-4-METHYLPHENYL)-6-(HYDROXYMETHYL)TETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; CHEBI:73274; 6S49DGR869; TA 7284; 928672-86-0; (1S)-1,5-anhydro-1-(3-{[5-(4-fluorophenyl)-2-thienyl]methyl}-4-methylphenyl)-D-glucitol; (1S)-1,5-Anhydro-1-C-[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]-D-glucitol; (1S)-1,5-Anhydro-1-(3-((5-(4-fluorophenyl)-2-thienyl)methyl)-4-methylphenyl)-D-glucitol; (1s)-1,5-anhydro-1-c-(3-((5-(4-fluorophenyl)-2-thienyl)methyl)-4-methylphenyl)-d-glucitol; (2S,3R,4R,5S,6R)-2-[3-[[5-(4-fluorophenyl)thiophen-2-yl]methyl]-4-methylphenyl]-6-(hydroxymethyl)oxane-3,4,5-triol; D-Glucitol,1,5-anhydro-1-C-[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]-, (1S)-; Canagliflozin/; JNJ 24831754AAA; (2S,3R,4R,5S,6R)-2-(3-{[5-(4-fluorophenyl)thiophen-2-yl]methyl}-4-methylphenyl)-6-(hydroxymethyl)oxane-3,4,5-triol; Canagliflozin [INN]; Tube102; JNJ 24831754; cc-209; MLS006011126; SCHEMBL157162; C24H25FO5S; GLU008; GTPL4582; CHEMBL2048484; HSDB 8284; BCPP000303; DTXSID601004469; ABP000358; BDBM50386885; CC0249; MFCD18251436; ZINC43207238; AKOS025401827; ACN-034470; BCP9000477; CCG-229581; CS-0522; DB08907; KS-1443; PB22925; NCGC00346691-02; (1S)-1,5-Anhydro-1-c-(3-((5-(4-fluorophenyl)thiophen-2-yl)methyl)-4-methylphenyl)-D-glucitol; AC-26303; HY-10451; SMR004702906; SW219119-1; A11100; Q-4516; J-500391; Q5030940; (1S)-1,5-anhydro-1-(3-{[5-(4-fluorophenyl)-2-thienyl]methyl}-4-methyl-phenyl)-D-glucitol; 1,5-Anhydro-1-(3-{[5-(4-fluorophenyl)thiophen-2-yl]methyl}-4-methylphenyl)hexitol; D-Glucitol, 1,5-anhydro-1-C-(3-((5-(4-fluorophenyl)-2-thienyl)methyl)-4- methylphenyl)-, (1S)-; D-glucitol, 1,5-anhydro-1-c-(3-((5-(4-fluorophenyl)-2-thienyl)methyl)-4- methylphenyl)-, (1s)-; D-Glucitol, 1,5-anhydro-1-C-[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]-, (1S)-
|
||||
Clinical Status |
Approved
|
||||
Disease Indication | Diabetes mellitus | ICD-11: 5A10 | [1] | ||
PubChem CID | |||||
Formula |
C24H25FO5S
|
||||
Canonical SMILES |
CC1=C(C=C(C=C1)[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F
|
||||
InChI |
1S/C24H25FO5S/c1-13-2-3-15(24-23(29)22(28)21(27)19(12-26)30-24)10-16(13)11-18-8-9-20(31-18)14-4-6-17(25)7-5-14/h2-10,19,21-24,26-29H,11-12H2,1H3/t19-,21-,22+,23-,24+/m1/s1
|
||||
InChIKey |
XTNGUQKDFGDXSJ-ZXGKGEBGSA-N
|
||||
Click to Show/Hide the Molecular Data (Structure/Property) of This API | |||||
Structure |
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=24812758"></iframe>
|
||||
3D MOL | 2D MOL | ||||
Physicochemical Properties | Molecular Weight | 444.5 | Topological Polar Surface Area | 118 | |
XlogP | 3.2 | Complexity | 574 | ||
Heavy Atom Count | 31 | Rotatable Bond Count | 5 | ||
Hydrogen Bond Donor Count | 4 | Hydrogen Bond Acceptor Count | 7 | ||
Full List of Drug Formulations (DFMs) Containing This API | ||||||
---|---|---|---|---|---|---|
Canagliflozin 100 mg tablet | Click to Show/Hide the Full List of Formulation(s): 1 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Anhydrous lactose; Magnesium stearate; Ferric oxide yellow; Talc; Titanium dioxide; Water; Croscarmellose sodium; Polyethylene glycol 3350; Hydroxypropyl cellulose (1200000 mw); Microcrystalline cellulose; Polyvinyl alcohol, unspecified
|
|||||
Dosage Form | Oral Tablet | |||||
Company | Janssen Pharmaceutical | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [2] | |||
Carmellose sodium | DIG Info | Albendazole monooxygenase (Protein expression upregulation) | [2] | |||
Polyethylene glycol 3350 | DIG Info | Albendazole monooxygenase (Protein expression upregulation) | [2] | |||
Canagliflozin 300 mg tablet | Click to Show/Hide the Full List of Formulation(s): 1 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Anhydrous lactose; Magnesium stearate; Talc; Titanium dioxide; Water; Croscarmellose sodium; Polyethylene glycol 3350; Hydroxypropyl cellulose (1200000 mw); Microcrystalline cellulose; Polyvinyl alcohol, unspecified
|
|||||
Dosage Form | Oral Tablet | |||||
Company | Janssen Pharmaceutical | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [2] | |||
Carmellose sodium | DIG Info | Albendazole monooxygenase (Protein expression upregulation) | [2] | |||
Polyethylene glycol 3350 | DIG Info | Albendazole monooxygenase (Protein expression upregulation) | [2] | |||
If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.